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Abstract: Since the realization that the cellular homologs of a gene found in the retrovirus that
contributes to erythroblastosis in birds (v-erbA), i.e. the proto-oncogene c-erbA encodes the nuclear
receptors for thyroid hormones (THs), most of the interest for THs focalized on their ability to
control gene transcription. It was found, indeed, that, by regulating gene expression in many tissues,
these hormones could mediate critical events both in development and in adult organisms. Among
their effects, much attention was given to their ability to increase energy expenditure, and they were
early proposed as anti-obesity drugs. However, their clinical use has been strongly challenged by the
concomitant onset of toxic effects, especially on the heart. Notably, it has been clearly demonstrated
that, besides their direct action on transcription (genomic effects), THs also have non-genomic effects,
mediated by cell membrane and/or mitochondrial binding sites, and sometimes triggered by their
endogenous catabolites. Among these latter molecules, 3,5-diiodo-L-thyronine (3,5-T2) has been
attracting increasing interest because some of its metabolic effects are similar to those induced by
T3, but it seems to be safer. The main target of 3,5-T2 appears to be the mitochondria, and it has
been hypothesized that, by acting mainly on mitochondrial function and oxidative stress, 3,5-T2
might prevent and revert tissue damages and hepatic steatosis induced by a hyper-lipid diet, while
concomitantly reducing the circulating levels of low density lipoproteins (LDL) and triglycerides.
Besides a summary concerning general metabolism of THs, as well as their genomic and non-genomic
effects, herein we will discuss resistance to THs and the possible mechanisms of action of 3,5-T2,
also in relation to its possible clinical use as a drug.
Keywords: thyroid hormone metabolism and transport; thyroid hormone mechanisms of action;
resistance to thyroid hormones (RTH); 3,5-diiodo-L-thyronine; hepatic steatosis; nonalcoholic fatty
liver disease; obesity
1. Introduction
Thyroid produces two main hormones: L-thyroxine (T4), and L-triiodothyronine (T3). The first
one is the predominant form (more than 80%) secreted by the gland and circulating, while T3 is
considered the most active form, since it binds with much higher affinity to the nuclear receptors [1–6].
In the periphery, the two hormones undergo deiodination, giving rise to other thyronines, some of
which have be found to have hormonal activity [7–9].
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Thyroid hormones (THs) are among the regulatory factors with the highest number of effects in
the human body. They do so through different mechanisms, the best understood of which rely on
their ability to bind nuclear receptors [1,10–14]. As discussed below, in the absence of active hormone,
the receptors associate with co-repressors and inhibit chromatin transcription, while, upon binding
with THs, they release co-repressors, bind co-activators, and stimulate transcription of those genes
they had inhibited before [15]. The real situation is actually more complex because some nuclear
receptor-mediated TH effects do not involve a direct binding of receptors to DNA [16]. In addition,
some rapid TH effects are mediated by hormone binding to plasma membrane sites, such as αvβ3
integrin [17], or to other cytoplasmic sites [14,18]. Finally, some catabolic products, once considered
inactive, such as 3,5-diodothyronine (3,5-T2), have been more recently found to have important effects
in the organism [19,20].
Obesity is an important risk factor for cardiovascular, degenerative, and malignant diseases [21–25].
Overeating can cause mitochondrial dysfunction, mainly in white adipose tissue (WAT). Mitochondrial
function alteration may in turn result in an altered substrate oxidation and increased oxidative
stress [26]. These events foster development of obesity and associated pathologies [27–31]. It is now
clear that THs regulate the expression of several genes involved in lipolysis, lipogenesis, thermogenesis,
mitochondrial function, and nutrient availability [32]. Given their action on metabolism, it seemed,
in the past, that they could be used as pharmacological agents for the treatment of obesity. However,
this approach could be not applied, due to adverse side effects on many organs and systems and,
in particular, on the cardiovascular system and the heart’s rhythm [33,34]. Yet, in recent years, it has
been found that some metabolites of thyroid hormones, and especially 3,5-diiodo-L-thyronine (3,5-T2),
are endowed with interesting metabolic activities that may be of clinical interest as possible therapeutic
options in the treatment of overeating disorders [20].
Herein, we will summarize some central aspects of TH metabolism and cellular action, both at
the genomic and non-genomic level. In addition, we will discuss resistance to THs and the possible
mechanisms of action of 3,5-T2, also in relation to its possible clinical use for the treatment of lipid
dysmetabolism and obesity.
2. Thyroid Hormone (TH) Metabolism
Synthesis and release of thyroid hormones is strictly controlled by the hypothalamic–pituitary–
thyroid axis (HPT axis) [35–37]. In response to a variety of physiologic and environmental stimuli,
hypothalamic neurons of the paraventricular nucleus (PVN) secrete the thyrotropin-releasing hormone
(TRH), which stimulates the anterior pituitary to produce the thyroid-stimulating hormone (TSH).
TSH regulates, in turn, all the steps of thyroid growth and function since the late fetal life [38]. On the
other hand, production of TRH and TSH is subjected to a negative control by THs [39]. HPT functioning
thus ensures constant levels of THs in the circulation. The epithelial cells of the thyroid gland
(thyrocytes) have the ability to concentrate iodide ions, thanks to a specific sodium/iodide symporter
(NIS or SLC5) present in their basolateral membrane [40–42], the synthesis of which is stimulated by
TSH [42]. In the case of iodine shortage, hypothyroidism follows. From this point of view, it is of
note that fluoride is able to inhibit NIS functioning through different molecular mechanisms, such as
inhibition of the Na+/K+-dependent ATPase, and upregulation of cytokines (including interleukins
IL-6 and IL-1β, and TGFα), that in turn inhibit biosynthesis of NIS [43].
Once in the epithelial cell, iodine is translocated across its apical membrane (iodide efflux) through
other transporters [42]. One of these transporters seems to be pendrin; however, there is no general
agreement about its actual role [19].
2.1. TH Synthesis, Release, and Transport to the Target Cells
The main products of the thyroid gland are L-thyroxine (T4) and triiodo-thyronine (T3).
Their synthesis involves different enzymatic steps, the first of which is iodination at position 3
or at both positions 3 and 5 of the aromatic ring of L-tyrosine residues, present in the protein
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thyroglobulin (TG) (Figure 1). The mono-iodinated (MIT) or di-iodinated (DIT) ring of a tyrosine
residue is then transferred to the ring of another di-iodinated tyrosine, thus forming triodo-thyronine
or tetraiodo-thyronine residues, respectively, both of which contain an inner tyrosine ring and an outer
phenolic ring; these residues are the immediate precursors of T3 and T4. Both synthetic steps are
catalyzed by a thyroid peroxidase (TPO), and take place in the lumen of thyroid follicles, in the so-called
colloid, mainly formed by thyroglobulin [42]. Both TG and TPO are thyroid differentiation markers
and function as autoantigens in thyroid autoimmune diseases like the Hashimoto thyroiditis [42].
Figure 1. Schematic drawing of the reactions leading to T4 (thyroxine) and T3 (triiodothyronine)
production and release from the thyroid gland. (A) General structure of one of the thyroid follicles:
Each follicle is formed by a layer of epithelial cells lining a central space filled with colloid, mainly
formed by the thyroglobulin; (B) synthesis of thyroid hormones (THs) starts by addition of iodine
atoms to position 3 or to both 3 and 5 positions of the aromatic ring of various tyrosine residues of
thyroglobulin (step 1). One mono-iodinated (MIT) or a di-iodinated (DIT) ring of a tyrosine residue
is then transferred (black arrows) to the ring of an adjacent di-iodinated tyrosine, thus forming
triodo-thyronine or tetraiodo-thyronine residues, respectively (step 2). The positions 3 and 5 of the
outer ring are now indicated as 3′ and 5′. Both step 1 and step 2 are catalyzed by a thyroid peroxidase
and take place in the lumen of follicles. (C) From time to time, as a response to thyroid stimulating
hormone (TSH), endocytosis of thyroglobulin into the epithelial cells that line the follicle and fusion of
endosomes with lysosomes allow digestion of thyroglobulin by proteases and release of the hormones
T3 and T4, as well as of other amino acids, including MIT and DIT. While these latter remain in the
gland, T3 and T4 are released into the blood through the basal membrane (BM).
From time to time, as a response to the thyroid-stimulating hormone (TSH), endocytosis
(both macro- and micropinocytosis) of thyroglobulin from the apical surface of thyrocytes that
line the follicle and fusion of endosomes with lysosomes allow digestion of thyroglobulin by proteases
and release of the hormones, as well as of other amino acids, including MIT and DIT (Figure 1).
Thyroglobulin thus functions both as a precursor for TH synthesis and as a storage of inactive
hormones in the lumen of follicles.
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Once secreted, THs are bound to TH distributor proteins (THDPs) that transport them in the
circulation. There are two main TH carriers in the blood: The thyroxine-binding globulin (TBG),
a monomeric protein of 54 kDa that shows higher affinity for THs, and transthyretin (TTR, previously
called thyroxine-binding prealbumin, TBPA), a symmetrical tetramer of 55 kDa, rich in beta sheet
structures [44,45]. In addition, albumin also binds THs even if with lower affinity than TBG and
TTR. Carriers have a dual function: They control the amount of free hormone, exchangeable with
the cells [1,37], and are responsible for the uniform distribution of circulating THs throughout the
body [44,45]. In addition to the above-mentioned carriers, it has been reported that THs and some of
their metabolites can also bind to low-density lipoproteins (LDL) [46].
Free THs enter the cells through transmembrane transporter proteins and not, as it had been
believed in the past, by passively crossing the plasma membranes. Since the 1970s it was found,
indeed, that TH transport was a saturable process. In more recent years, a variety of carriers have been
found to be involved in TH transport across the plasma membrane. Among them, three families play a
major and more specific role, as indicated by the effects of their mutation: (1) The monocarboxylate
transporters (MCT) 8 and 10, (2) the L-type amino acid transporters (LATs), and (3) the organic
anion transporters (OATPs, SLC10, and SLC17) [37,47–49]. MCT8 is also present in the basolateral
membrane of thyrocytes and is critical for secretion of THs [37,47]. Mutations of MCT8 were already
reported to be associated with severe intellectual disability many years ago [50] and, more recently,
it was found that mutations in the OATP1C1 transporter associate with severe brain hypometabolism
and juvenile neurodegeneration [49,51]. These observations demonstrated that serious symptoms of
hypothyroidism can be caused by deficits of TH membrane transporters, and the resulting inability of
the hormones to enter the cells in sufficient amount.
2.2. Activation and Inactivation of THs by Deiodinases
As mentioned, the main form of THs secreted from the thyroid gland and circulating is T4, while T3
is considered the active hormone as it binds with the highest affinity to the nuclear receptors [1–6].
Although a small amount of T4 is converted to T3 in the thyroid itself, conversion of T4 into its
active form takes place mainly in the target cells (Figure 2). Both in the thyroid and in the periphery,
metabolism of THs involves deiodinases (DIOs), a family of enzymes that consists of three members:
(1) DIO1 that catalyzes deiodination of both the outer and inner rings of iodothyronines, (2) DIO2 that
catalyzes deiodination of the outer, phenolic ring (ORD), and (3) DIO3 that catalyzes deiodination of
the inner tyrosine ring (IRD) [37]. All DIOs belong to the thioredoxin fold superfamily and contain
a selenocysteine in the active site [8,48,52]. The three isoforms differ for intracellular localization:
DIO1 and DIO3 localize to the plasma membrane, while DIO2 is an endoplasmic reticulum resident
protein. Moreover, under ischemia/hypoxia, DIO3 is rapidly redirected to the nuclear envelope, where it
inactivates T3 [3]. DIO2 has been demonstrated to play a critical role in the brain, where it is mainly
present in astrocytes: T4 enters these latter cells, is deiodinated to T3, and is then transferred through
MCT8 to neurons, where it binds to TH nuclear receptors or is degraded to 3,3′-T2 by DIO3 [3,53].
Notably, DIO3 is encoded by an imprinted gene, and its expression changes during development as
well as across different regions of the brain. The epigenetic nature of DIO3 expression regulation
introduces a further level of temporal and regional modulation of brain cell ability to respond to
THs [54].
DIO2 has been also reported to play a central role in T4-mediated feedback mechanisms in the
HPT axis: In the hypothalamus, DIO2 is highly expressed in tanycytes, specialized ependymal cells
located close to the TRH-producing neurons of the PVN. Tanycytes receive T4 and transform it into T3,
which then reaches PVN and the pituitary gland [3,55]. A special property of DIO2 is its relatively
short half-life, due to TH-dependent, post-translational regulation by ubiquitination and degradation
by the proteasome [56]. Interestingly, it has been reported that the polymorphism Thr92-to-Ala
(Ala92-DIO2) causes endoplasmic reticulum (ER) tress, thus activating the unfolded protein response
(UPR). Ala92-DIO2 tends, indeed, to accumulate in the trans-Golgi. As a consequence, less T3 is
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produced; this situation can be improved by eliminating ER stress with the chemical chaperone
4-phenyl butyric acid (4-PBA) [56]. Notably, Ala92-DIO2 polymorphism has been also associated
with insulin resistance [57]. In particular, it has been suggested that a decreased local production
of T3 because of DIO2 malfunctioning can influence the expression of the insulin-sensitive glucose
transporter 4 (GLUT4), in adipocytes and skeletal muscle cells; the gene encoding GLUT4 is indeed a
T3 target gene [58].
Figure 2. Metabolic pathways leading from the prohormone T4 to the active hormone T3 and to
other inactive/active derivatives of THs (see below). Deiodinases probably involved in each transition
are indicated.
The three classes of deiodinases also differ for their tissue distribution: Under physiological
conditions, DIO1 is mainly expressed in the thyroid gland, liver, and kidney; DIO2 in the thyroid gland,
brain, skeletal muscle, and brown adipose tissue; and DIO3 in brain and pancreas [8,59].
As shown in Figure 2, both DIO1 and DIO2 are able to transform T4 into T3, with DIO2 having a
higher affinity for the hormone (Michaelis-Menten constant, Km,, in the range of 1-4 nm) than DIO1
(Km in the range of 1–0 µm) [8]. Given the already mentioned differences in the half-life and localization
of the two enzymes, however, it is not easy to establish which enzyme has the highest impact on local
T3 formation. Intriguingly, it has been reported that the DIO1/DIO2 double knock-out (KO) mice
appear healthy, and even show normal serum T3 levels [60]. The authors suggested that the two
enzymes were not essential for the maintenance of the serum T3 level, but that they (and in particular
DIO2) did have an important role in thyroid hormone local homeostasis [9,60].
3. Cellular Mechanisms of Action of THs
The best known mechanisms of action of THs rely, similarly to steroids, on direct effects on
transcription regulation, mediated by nuclear receptors. These effects become evident after a time
lag during which synthesis of RNA and proteins is required. However, some cellular activities are
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immediately stimulated by THs, suggesting that other mechanisms are also in action. As reported
below, these further activities are collectively indicated as “non-genomic”.
3.1. Thyroid Hormone Receptors (TRs)
The existence of receptors for THs (TRs) in the nucleus was already known since the 1970s,
and it was also shown that they had a much higher affinity for T3 than for T4 [9,61,62]. In the
1980s, when different steroid receptors, as well as the TRs, were cloned, it became evident that
they all belonged to a superfamily of structurally related nuclear proteins that recognized specific
DNA response elements present in the target genes [63–66]. In particular, TRs were identified as the
products of the cellular c-erbA α and β proto-oncogenes, present on human chromosomes 17 and 3,
respectively [65–67]. The two genes were demonstrated to give rise, by alternative splicing, to different
variants, some of which were not able to bind THs because the splicing events eliminated part of the
hormone-binding domain [68–72]. Notably, one of these splicing isoforms not able to bind T3 (α2) is
highly expressed in the brain [12,73,74]. As shown in Figure 3A, α and β isoforms share a common
structure [10–12,75–78], that includes: (1) An N-terminal A/B domain, of variable length, endowed
with modulatory functions and an effect on transcription transactivation (activation function 1, AF1).
The A/B domain also contains a nuclear localization signal (NLS) fundamental for TRα1 import into
the nucleus (see below). The activity of this domain can be modified by post-translational events,
such as phosphorylation [79] and acetylation [80]; (2) a highly conserved DNA-binding domain (DBD,
C domain), which includes two “zinc fingers”, able to interact with the DNA double helix. In particular,
in each zing finger, four invariable cysteines form a tetrahedrical coordination structure with a Zn2+ ion.
Some amino acids present at the base of the first Zn-finger are required for recognizing specific DNA
motifs [81], while some residues of the second zinc finger are involved in receptor dimerization [75];
(3) a hinge domain (D) that contains a NLS for both TRα1 and TRβ and can participate in interactions
with receptor co-regulators. It has been also proposed that the D domain might form extensions of the
DBD and the hormone binding domain (HBD) or unfold to permit TRs to adapt to different thyroid
hormone response elements (TREs) [82]; (4) HBD (E domain), that contains residues necessary for
hormone recognition as well as multiple contact surfaces that mediate homo- and hetero-dimerization
and the interaction with other regulatory proteins; and, finally, (5) a C-terminal domain (F domain),
endowed, like the N-terminal domain, with transactivation of transcription function (AF2) [67].
Much of the action of TRs depends on interaction with the already mentioned DNA sequences
called TREs, present in the regulatory regions of the TH target genes and formed by two half-sites,
each including at least the AGGTCA hexamer consensus motif, separated on average by four
nucleotides [12,16,72,78,83]. The two half-sites can be organized as direct repeats as well as palindromic
and inverted repeats [78,81,84]. DNA motifs recognized by different nuclear receptors can differ for
the sequence of the two half-sites as well as for the number of nucleotides present in between them.
For example, it was shown that TREs containing direct repeats can be converted into retinoic acid
response elements (RREs) by increasing the spacing between the half-sites by one single nucleotide,
while, decreasing the spacing, again by a single nucleotide, converted them into vitamin D3 response
elements (DREs) (81). These early results were a clear demonstration of the importance of the spacing
between the repeats for determining the affinity and specificity of DNA motifs for different regulatory
molecules. Notably, the hexamer sequence of the two half-sites can also differ in different natural TREs,
suggesting that variability of the repeats might influence responsiveness of different genes to THs [85].
In most cases, nuclear TRs form heterodimers with the retinoic acid X receptors (RXR) that also
belong to the superfamily of nuclear receptors. In particular, the RXR component of the heterodimer
was found to bind to the 5′ repeat of the TRE, while the TR protein binds to the 3′ repeat [84]. However,
in some cases, TRs bind to DNA as monomers or homodimers [86], and it was demonstrated that each
species (TR, TR/TR, and RXR/TR) exhibits preferences for different TREs [87,88]. Some isoforms of TR
β have been even reported to bind as trimers to some naturally occurring TREs [83].
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Figure 3. (A): Schematic drawing of the domain structure of thyroid hormone nuclear receptors (TRs).
Each isoform contains: (1) An N-terminal A/B domain, of variable length, (2) a highly conserved
DNA-binding domain (DBD, or C domain), (3) a hinge D domain, (4) the hormone-binding domain
(HBD or E domain), and, finally, (5) a C-terminal domain (F domain). * This isoform was only found in
rat [77,89]. ** These isoforms are not able to bind hormones [12,77]. (B) The mature mRNA encoding
TRα1 can give rise to different isoforms, depending on the AUG from which translation begins.
The truncated isoforms are shorter at the N-end, but have an unaltered hormone-binding domain. NLS,
nuclear localization signal; MIS, atypical mitochondrial import sequences (MIS), that mediate import of
p43 and p28 to the mitochondrial matrix and the inner mitochondrial membrane, respectively [14,18]
(discussed in Section 3.3).
Another classic paradigm of TR function states that most of the known TREs are ‘positive’ regulators
at which transcription is repressed by TRs, in the absence of hormone, and activated by T3-bound TRs.
However, some TREs are ‘negative’ regulators that operate in the opposite direction: Transcription is
stimulated by hormone-free TRs, while it is repressed by T3-bound TRs [11,76,85,90,91]. Both positive
and negative effects of TRs depend on interaction with co-regulators, known as “co-activators” and
“co-repressors”, respectively [37,92–94] (Figure 4).
In more detail, when TRs are bound to ‘positive’ TREs in the hormone-free form, they are part
of co-repressor complexes that include the nuclear corepressor (NCoR), the silencing mediator for
RXR and TR (SMRT), and histone deacetylases (HDAC). These latter enzymes also associate with
methyl-CpG-binding proteins, thus contributing to methylation-dependent gene silencing [12,37,95].
Int. J. Mol. Sci. 2020, 21, 4140 8 of 40
Figure 4. Canonical model of TR interaction with thyroid hormone responsive elements (TRE).
When TRs are bound to ‘positive’ TREs in the hormone-free form, they are part of co-repressor
complexes that repress transcription (A). On the other hand, in the hormone (H)-bound form, TRs form
co-activator complexes that activate transcription (B). Although TRs can bind to chromatin as monomers
as well as homodimers, they often bind TREs as heterodimers with the retinoic acid X receptor (RXR),
another member of the nuclear receptor family; in this latter case, the RXR component of the heterodimer
was found to bind to the 5′ repeat of the TRE, while the TR protein bound to the 3′ repeat.
On the other hand, in the hormone-bound form, TRs are part of coactivator complexes that
include the steroid receptor coactivator 1 (SRC-1), also known as nuclear coactivator 1 (NCoA-1),
the transcriptional intermediary factor 2 (TIF2/GRIP-1/NCoA-2), the cAMP-response element binding
protein (CREB)-binding protein (CBP), also known as p300, the p300/CBP-associated factor (p/CAF),
the vitamin D receptor-interacting protein/TR-associated protein (DRIP/TRAP), and the mediator
complex subunit 21 (MED/21, also known as Srb7) [75,96–100]. Notably, many co-activators have
histone acetyltransferase (HAT) activity [101–103]. Histone acetylation is indeed a well-known
mechanism to remodel chromatin structural organization in order to allow interaction of the basal
transcription factors with the gene promoters [104]. In some cases, HAT can also acetylate non-histone
proteins, including basal transcription factors themselves, such as TFIIE and TFIIF [105]. Probably,
in many cases, T3-bound TRs can function as pioneer factors, able to “open” chromatin structure,
allowing other transcriptional factors to gain access to gene promoters [16,106].
As mentioned above, in a few cases, hormone-bound TRs repress transcription. Although the
mechanisms underlying this second type of hormone action are less clear, it seems that TRs might
interfere, in a T3-dependent manner, with the activity of other transcriptional factors, thus inhibiting
their function and, as a consequence, gene transcription. For example, it has been reported that
both TRβ1 and TRα1 interfere with the binding of the TEAD/TEF transcription factors (TEADs) to
a specific sequence present in the promoter of the gene encoding myosin heavy chain 7 (MYH7),
in a T3 dose-dependent way. As a consequence, TEADs that are the main activators of MYH7 gene
transcription in the heart of rodent embryos are no longer able to activate transcription after birth,
when circulating T3 concentration increases [107]. Similarly, T3-bound TRs are able to inhibit the
expression of the gene encoding the β subunit of TSH (TSHβ) [108–111] and the gene encoding
DIO2 [112], in the pituitary, by a tethering mechanism that prevents the binding of pituitary-specific
transcription factors, such as Pit-1 and GATA2 [112].
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More recently, indeed, it became clear that the canonical model drawn in Figures 4 and 5A is not
the only mechanism of action of TRs [14,16,72,113]. For example, experiments based on chromatin
immunoprecipitation and sequencing (ChIP-Seq) demonstrated that TRs can be bound to sequences
other than TREs, sometimes not present in the gene promoters [88,114]. Thus, it has been envisaged that
TRs can also interact with chromatin in an indirect manner, by tethering to other chromatin proteins
(Figure 5B, type 2 of TR action). In addition, their activity can be even independent of both direct and
indirect chromatin binding (Figure 5C, type 3 of TR action); in this latter case, TR can function both
in the nucleus and in the cytoplasm [16]. Finally, as we will discuss in Section 3.3, TH action can be
completely independent of the nuclear receptors (type 4 action of thyroid hormones) [16], although at
least some of these so-called “non-genomic” functions of TH actually rely on truncated isoforms of
TRs that localize to parts of the cell other than the nucleus [14,15,18,115].
Figure 5. Possible alternative ways of action of TRs. (A) Canonical way of action: TRs can interact
with DNA elements called thyroid hormone responsive elements (TRE) as monomers, as homodimers,
or as heterodimers with RXR; (B) TRs can interact with chromatin in an indirect way, by tethering to
another chromatin-bound protein; (C) the action of TR can be independent of both direct and indirect
chromatin binding [16].
On the basis of the complexity of TR mechanisms of action, it can be expected that a further level of
regulation of TR action is their trafficking between nucleus and cytoplasm. Recently, it has been found
that nuclear entry of TRα1 is mediated by interactions of the nuclear transport proteins importin 7,
importin β1, and the adapter importin α1 with the nuclear localization motifs (NLS1 and NLS2) present
on the receptor [116]. Interestingly, TRβ1, which lacks NLS-2, tends to show a slightly more cytosolic
localization [14,80]. Similarly, exit from the nucleus requires nucleus export signals (NES) that are
present in the hormone-binding domain [117]. As a whole, these observations suggest that the nuclear
action of THs also depends on the amount of active TRs that enter the nucleus [118]. As a consequence,
TR post-translational modifications, by tuning this ability, can also affect TH activity. For example,
TR phosphorylation modulates DNA binding, gene transcription, and even nuclear localization [79].
Moreover, both the DBD and HBD have been demonstrated to undergo sumoylation [119]. Interestingly,
it has been recently reported that non-acetylated forms tend to be retained in the nucleus, while, on the
contrary, acetylation promotes cytosolic localization [80]. A further example of post-translational
modification is ubiquitination that targets hormone-bound TRs for degradation [120].
As we will discuss in the next paragraph, the described functions of TRs can be affected at many
levels; for example, their genes can harbor mutations that inhibit, or completely abolish, their ability
to bind DNA or hormone; alternatively, epigenetic modifications of chromatin organization of TR
encoding genes can inhibit or enhance TR production. These events, together with the already
mentioned genetic or epigenetic modifications of transporters and enzymes involved in TH metabolism
Int. J. Mol. Sci. 2020, 21, 4140 10 of 40
and delivery to tissues, can cause apparent conditions of hypo- or hyperthyroidism, in the presence of
normal concentrations of circulating hormones.
3.2. TH Resistance
Notably, the three hormone-binding TR isoforms have different tissue distributions [71,72,121]:
TRα1 is predominantly expressed in bone, central nervous system, cartilage, heart, skeletal muscle,
and gastrointestinal tract; TRβ1 in liver and kidney; and TRβ2 in hypothalamus and pituitary (where it
is responsible for the feedback control exerted by THs on the HPT axis) [122], as well as in inner ear and
retina. Although the affinity for T3 is quite similar for all the isoforms, as mentioned above, each kind
of TR can have a different intracellular localization pattern. Most important, the unequal α and β
isoform tissue distribution brings about different effects on the organism in case of mutation of the
corresponding gene (THRA or THRB, respectively).
The existence of peculiar syndromes due to resistance to thyroid hormones (RTH) has been
known for more than five decades [123]. In more recent years, the cause of these syndromes was
attributed to mutations of THRA or TRHB, and the corresponding syndromes are now called RTHα
and RTHβ, respectively [37,72,123–125]. As can be expected from the main mechanism of action
of TRs, mutations affecting the HBD (E/F domain) interfere with hormone binding to TR and have
a dominant negative effect on THs action: TRs remain stably bound to the TREs in the repressive
hormone-free form [77,121,126–128]. On the other hand, mutations that involve the DBD are much less
serious than mutations that involve the HBD: When TRs are not able to bind DNA, target genes are
probably left in neutral state, in which they are neither activated by hormone-bound TRs nor repressed
by hormone-free-TRs and, indeed, the dominant negative effect of a TRβ, mutated in the HBD, can be
counteracted by introducing into the DBD a mutation that impedes binding to TREs [129]. Moreover,
it has been found that mutations of the co-repressor NCoR that abolish its interaction with TR [130],
or treatment with inhibitors of HDAC [131], in a murine model of RTHα, both improve phenotypic
abnormalities. Recently, it has been reported, however, that treatment of mice with the HDAC inhibitor
suberoylanilide hydroxamic acid (SAHA) does not seem to improve the skeletal disorders due to
RTHα [132].
The first case described of a familial RTH syndrome was characterized by deaf-mutism, stippled
epiphyses, goiter, and abnormally high levels of protein-bound iodine [123]. Since then, many other
clinical symptoms have been identified that can be attributed to target organ resistance to thyroid
hormones. Based on analyses done in Europe, North and South America, and Asia, the incidence
of resistance (about 90% RTHβ) is estimated to be around 1:50,000 live births [72]. Notably, given
the different tissue distribution of TRα and TRβ, the pathological outcomes are different, depending
on the mutated TR gene. The most common signs of RTHβ are goiter, attention deficit disorders,
and resting tachycardia, but severity of the symptoms can vary depending on the specific mutation in
TRB gene and even among individuals who bear the same mutation [72]. Probably, the main defects
underlying RTHβ correlate with TRβ2-dependent modulation of the HPT axis: When TRβ is mutated,
the negative feedback, normally exerted by THs on the hypothalamus and pituitary, is impaired; as a
result, the levels of TSH tend to increase and the thyroid gland is continuously stimulated, so that both
its volume (goiter) and TH production increase. TH increase partially compensates for TRβ resistance
in those tissues that rely on TRβ. On the other hand, tissues that rely on TRα (for example, the heart)
experience a hyperthyroidism-like condition (Figure 6, RTHβ) [37,72,133].
Up to now, more than 160 mutations in TRβ (mostly single nucleotide substitutions, but also
deletions, frameshifting, and nonsense modifications that generate stop codons) have been identified.
Most TR mutations are familial; some, however, are sporadic [72,134,135].
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Figure 6. Mutations in genes encoding the thyroid hormone receptor α (TRα, gene: TRA) and the
thyroid hormone receptorβ (TRβ, gene: TRB) cause resistance to thyroid hormones (RTH), with different
effects on peripheral tissues, depending on the TR isoform expressed. In the presence of inactivating
mutations of TRα (RTHα), tissues relying on this isoform of TR experience a hypothyroidism-like
condition: the hypothalamic-pituitary-thyroid (HPT) axis is indeed unaffected. Thus, THs exerts a
normal negative feedback (the red minus sign, in the figure), and there is no compensatory increase of
circulating THs. In the presence of inactivating mutations of TRβ (RTHβ), mutated TRβ2 does not bind
T3 and does not inhibit production of TRH and TSH in the hypothalamus or pituitary, respectively; thus,
T4/T3 levels increase. As a consequence, peripheral tissues relying on TRβ1 isoform (liver and kidney)
can have almost normal responses to THs because the increased levels of circulating THs compensate
for the decreased ability of TRβ to bind them. On the other hand, tissues relying on TRα experience a
hyperthyroidism-like condition because of the increased levels of THs. CNS, central nervous system;
SM, skeletal muscle; GT, gastrointestinal tract.
Mutations in THRA are rare and account only for a small proportion of all TR genetic
modifications. For decades no THRA mutation was identified at all, and it was even believed
that TRα loss of function might have been incompatible with life. To date, about 20 missense and
frameshift mutations of THRA have been described [121,136–140]. Clinical features of patients include
many symptoms commonly present in hypothyroidism, such as bradycardia, constipation, skeletal
dysplasia (macrocephaly, late fontanelle closure, and epiphyseal dysgenesis), delayed bone growth and
psychomotor development, and intellectual disability [72,121,141]. In other words, the pathological
signs involve those tissue that normally rely on TRα. On the other hand, the HPT axis is unaffected
and there is no compensatory increase of circulating THs (Figure 6, RTHα). As in the case of RTHβ,
a large variability of severity can be observed, depending on the specific mutation [137].
In one patient affected by all the symptoms described above, also epilepsy was observed [142].
Moreover, a de novo missense mutation (R384C) in TRα1 was found in a patient affected by an autism
spectrum disorder [143]. Recently, it has been reported that TRα1 is required for normal neural
progenitor cell proliferation in human cerebral cortical development; as a consequence, mutations in
the TRA gene cause a reduction of brain size and intellectual disability [141].
Notably, somatic mutations in TRs have been also found in some cancers, such as human
hepatocellular carcinoma, renal clear cell carcinoma, breast cancer, pituitary tumor, and thyroid
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cancer [14,144,145]. These observations suggested that TRs can also have a tumor suppressive
role [146,147].
As a final comment on TH resistance, it is worth noting that, in some patients with RTH,
no mutation was found in TRs [148], in their co-regulators [149], or in enzymes involved in TH
transport and metabolism. The same observation has been done for cancer cells. Now, a variety of
recent studies suggest that deregulation of gene expression is very often caused by epigenetic factors,
such as alteration of DNA methylation pattern and/or of histone post-translational modifications.
Moreover, it is becoming increasingly clear that epigenetic effects can also depend on deregulation
of the expression of specific microRNAs (miRNAs), short RNAs, about 22 nucleotides in length,
that recognize complementary sequences (microRNA recognition elements, MREs) present on target
mRNAs: Pairing results in the repression of target mRNA translation or even in its degradation [150].
In line with this idea, it has been reported, for example, that in renal cancer, miR-155 and miR-425
are upregulated and that their increase is inversely correlated with the cell content of TRβ [151].
Similarly, studies performed in cardiac and skeletal muscle have suggested that a group of miRNAs
(including miR-133, miR-208a, miR-208b, and miR-499) might mediate/modulate TH signaling in these
tissues [152,153].
3.3. Non-Genomic TH Action
In addition to the mechanisms of action already discussed, some TH functions can be, at least in
part, also independent of nuclear receptors (type 4 of thyroid hormone action) and take place outside
the nucleus [16]. The extra-nuclear pathways are defined “non-genomic” [15,154–159] to distinguish
them from the canonical regulation of gene transcription, defined “genomic”, and mediated by TRs.
However, they can eventually affect transcription, too, and can be mediated by alternatively spliced
isoforms of TRs (see below).
More than five decades ago, the existence of TH receptors at the plasma membrane had been
already hypothesized, and these sites were proposed to be involved in the rapid onset of some cellular
responses to the hormones, even elicited in conditions of transcriptional blockage [1,160–162]. A large
body of evidence then confirmed that THs can trigger signal transduction pathways initiated at
the plasma membrane and often mediated by secondary messengers, such as Ca2+ ions, inositol
trisphosphate (IP3), and cAMP [154,155,163,164]. Moreover, a plasma membrane-binding site was
identified as integrin αvβ3, a member of the family of proteins that mediate the bidirectional interaction
between the cell and the extracellular matrix (ECM) and regulate the organization of tissues as well
as cell migration processes [15,157,165,166]. The αvβ3-dependent pathway is mostly sensitive to T4
and activates intracellular kinases, such as protein kinase B (PKB/AKT), and the mitogen-activated
protein kinase (MAPK) that in turn phosphorylate intracellular proteins, some of which act in the
nucleus and can regulate transcription. Notably, this pathway can also stimulate cell proliferation and
may have a role in different cancer types, such as T-cell lymphoma (TCL), colorectal cancer (CRC),
and glioma [166–168]. By binding to αvβ3 in cancer cells, T4 activates transcription of a variety of genes
that can stimulate cancer growth, such as genes with a function in signal transduction, angiogenesis,
regulation of actin cytoskeleton, and epithelial-mesenchymal transition [168–170]. Interestingly,
non-malignant cells express less αvβ3 than normal cells and, in addition, the conformation of the
protein in normal cells seems to have a lower signal transduction activity [168].
The hormone-binding site on αvβ3 was initially identified with the Arg-Gly-Asp (RGD) amino
acid sequence that also mediates cell binding to ECM proteins [171]. More recently, however, it has
been suggested that the receptor site is more complex and includes a T3-binding site (S1) besides a
T3/T4 binding site (S2), with a lower affinity for T3. Since, in physiological conditions, T3 is much
less concentrated than T4 outside the cell, the probability that T4, and not T3, binds S2 is much
higher [166,172]. The signaling triggered by T3 binding to S1 involves the phosphoinositide 3-kinase
(PI3K)/PKB(AKT) pathway, which does not seem to regulate cell proliferation, but can modulate the
shuttling of regulatory proteins, including TRα, from the cytoplasm to the nucleus [15,172].
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In fact, activation of PI3K was also suggested to be mediated by a direct binding of cytoplasmic
TRβ to the regulatory subunit (p85) of the enzyme [173]. The ability to bind the regulatory subunit of
PI3K has been also reported for TRα1 [174]. In any case, activation of PI3K stimulates transcription of
genes, such as the hypoxia-inducible factor (HIF)-1α [173].
The plasma membrane receptor site present on integrin αvβ3 is not the only extra-nuclear binding
site for THs. Other “receptors” are also present in the cytoplasm. Notably, four proteins (p43, p33,
p30, and p28) have been identified, which are encoded in the same mature mRNA that also encodes
TRα1 [175]. This mRNA can be also translated starting at internal AUG triplets, thus resulting in proteins
that are shorter than TRα1 at the N-end [14] (Figure 3B). The full-length protein contains, as mentioned,
at least two signals for nuclear localization (NLS); in addition, it contains atypical mitochondrial
import signals [176] that probably are not active when both NLS are present. The truncated translation
products lack one or both NLS and their localization might thus be influenced by other signals. We can
also suppose that exposure of the localization signals is influenced by the conformation of the proteins,
and that conformation can be influenced by the length of the N-terminus.
In human primary osteoblasts (hPOBs) and mouse osteoblast-like MC3T3 cells, the TRα1 truncated
isoform p30 was found to be modified by palmitoylation and inserted into the inner leaflet of the
plasma membrane, where it colocalized with caveolin-1 [115]. In this position, p30 could bind THs,
thus activating a signal transduction pathway that resulted in increased intracellular concentrations of
calcium ions, nitric oxide (NO), and cyclic guanosine monophosphate (cGMP), leading to activation of
the cGMP-dependent protein kinase II (PKGII) [115]. On the other hand, in rat liver mitochondria
prepared by differential centrifugation and purified through sucrose gradients, p43 was found to
localize to the mitochondrial matrix [177]. Finally, p28, the activity of which still remains unclear,
was found at the level of the mitochondrial inner membrane [18]. Gel shift experiments demonstrated
that p43 can also recognize canonical TREs, with an affinity similar to that of nuclear full-length
receptors. Notably, the mitochondrial genome contains four TRE-like sequences that can bind p43 in
gel shift experiments [18]. Moreover, it was found that over-expression of p43 induced large increments
of both mitochondrial activity and mitochondriogenesis; these effects can be abolished by deleting the
DNA-binding domain of the protein [18].
Interestingly, it was also reported that there is mitochondrial localization of TRα2, the dominant
negative isoform lacking a functional HBD. Moreover, by electromobility shift assays, it was shown
that TRα2 binds to TREs present in the 12S rRNA gene and D-loop region of mitochondrial DNA [178].
All these findings, together with the fact that mitochondrial isoforms of other hormone receptors,
including mtRXR, have been also identified [179], provide evidence that thyroid hormones have direct
effects on mitochondria and, probably, with mechanisms that, at least in part, resemble the nuclear
ones. An interesting hypothesis is that a TH-mediated interplay may exist between the nuclear and
the mitochondrial genome [180]. The framework becomes even more complex when we consider the
existence of TH metabolites with specific roles, only partially superimposable to those of the main THs.
In the next paragraphs we will consider, in particular, the hormonal properties of 3,5-T2.
4. The 3,5-Diodothyronine (3,5-T2) as a Hormone
In spite of their wide effects on metabolism, the use of THs for therapeutic purposes remains
controversial because, as mentioned, these hormones may induce other non-metabolic effects. In more
detail, like hyperthyroidism, treatment with exogenous THs can induce thyrotoxicosis, a condition
characterized by a variety of adverse symptoms, such weight loss, osteoporosis, atrial fibrillation,
embolic events, and increased risk of heart failure [33,34,181].
In the last two decades, however, much attention has been devoted to TH metabolites,
and especially to 3,5-T2. As discussed below, indeed, 3,5-T2 has some T3-like effects [182–187]
in the absence of thyrotoxic side effects, at least when used at low concentrations [20,188]. On the
contrary, at higher concentrations, it has been reported to suppress TSH and the HPT axis [189–191]
and even to cause adverse cardiac effects similar to those observed in hyperthyroidism [190].
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Early studies indicating a physiological role of 3,5-T2 were initially overlooked because the
molecule was considered only an inactive metabolite of thyroid hormones T3 and T4. This interpretation
was based on the observations that 3,5-T2 had a low affinity for TRs [113,183]. Thus, most of the
available studies on THs mainly dealt with T3; as discussed above, indeed, thyroid hormone receptors
showed a higher affinity for this TH form. However, at the end of 1980s and the first years of the
1990s, after finding that thyroid hormones also had non-genomic effects, the putative role of 3,5-T2
was re-evaluated and investigations began to be directed at assessing the metabolic effects of this
molecule [183,192–196].
As summarized below, many experimental observations have shown that 3,5-T2 administration
to rodents caused an increase in the resting metabolic rate (RMR) [185,197] and prevented overweight
and insulin resistance induced by a high-fat diet (HFD) [198,199]. Furthermore, the administration
of 3,5-T2 to HFD rats seems to protect animals from the onset of non-alcoholic fatty liver disease
(NAFLD) [191], although this finding has been challenged by results obtained in Sprague–Dawley rats
fed an unsaturated fat diet, in which 3,5-T2 failed to improve NAFLD and insulin sensitivity [200]. It is
worth noting, however, that 3,5-T2 has been suggested to influence glucose metabolism not through
effects on insulin sensitivity, but by reducing hepatic glucose transporters 2 (GLUT2) and glucose
output from the liver [201].
In humans, demonstration of 3,5-T2 physiological effects and, in particular, of its benefits
on obesity and related diseases is still equivocal because of the lower number of experiments
performed, and also for the difficulties encountered in measuring 3,5-T2 concentration in human serum.
An antibody-based competitive chemiluminescence immunoassay (CLIA) [202] was used to investigate
serum concentration of 3,5-T2 in humans under both physiological and pathophysiological conditions;
the results suggested that 3,5-T2 concentrations do not differ in hyperthyroid (0.31 ± 0.02 nm) compared
to hypothyroid (0.43 ± 0.04 nm) individuals [202]. More recently, HPLC coupled to tandem mass
spectrometry [203] allowed a more accurate 3,5-T2 detection in human serum (the average concentration
reported was 78± 9 picomoles/liter) [203]. In general, significant differences still remain among different
detection methods. Thus, the data reported in the literature are not uniform. In addition, given the
already discussed existence of different DIOs, with different activities, in peripheral tissues, we cannot
exclude that the concentration of 3,5-T2 is different in tissues with respect to blood. A further problem
arises from the degree of purity of commercial preparations of 3,5-T2, used as standards in the
measurements; these preparations are, indeed, frequently contaminated with T3 [20,204]. Even with
these limitations, 3,5-T2 is now widely considered a bioactive molecule with dose-dependent effects on
physiological regulatory functions [20,59,113,191,204–211].
4.1. The 3,5-T2 Production in the Cell and Its Effects on Rest Metabolic Rate (RMR)
Many observations suggested that 3,5-T2 might derive from T3 by deiodination (Figure 2).
As an example, both T3 and 3,5-T2 stimulated oxygen consumption by isolated perfused livers from
hypothyroid rats at a concentration as low as 1 pM within 90 min, but 3,5-T2 gave rise to a faster
stimulation than T3 [212]. Moreover, inhibition of DIOs by propylthiouracil (PTU) abolished the
rapid stimulation of oxygen consumption by T3, but not the effects of 3,5-T2. These data suggest
that the peripheral deiodination of T3 is a key metabolic step in the production of 3,5-T2 and
that this latter molecule has the same power as T3, but exerts its effect more rapidly because it
does not require deiodination [212]. Starting from these observations, further studies were carried
out to better understand the effects of 3,5-T2 on energy metabolism, and on cellular respiration.
The administration of 3,5-T2 to experimental animals was confirmed to induce more rapid effects,
on oxidative phosphorylation (OXPHOS), than those obtained with T3: While 3,5-T2 activity was
evident one hour after the injection, T3 activity was evident only after 24 h [213,214]. Notably, the effect
of 3,5-T2 was found to be independent of protein synthesis: It was not influenced by the protein
synthesis inhibitor cycloheximide [215]. These early experiments also suggested that the effects of
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3,5-T2 were mediated by a direct effect on mitochondria, while those of T3 depended primarily on
nuclear events [194].
It follows that, if 3,5-T2 can influence the rate of energy consumption by mitochondria, the hormone
probably has an effect on the energy metabolism of the whole animal. This hypothesis was also
supported by previous studies in which the changes of the RMR, after administration to hypothyroid
rats of single doses of 3,5-T2 or T3, had been monitored and compared [216–218]. From these
experiments, however, it was not clear whether the effects on RMR were effectively due to the hormones
or to their metabolites. This is the reason why, in other experiments, as mentioned, deiodinases were
simultaneously inhibited by the administration of propylthiouracil (PTU) and iopanoic acid (IOP).
This treatment induced a marked inhibition of all the three types of deiodinases, and, at the same time,
severe hypothyroidism in animals. In particular, PTU inhibited the production of thyroid hormones
by the thyroid gland, via inhibition of both the thyroid peroxidase activity, and DIO1. On the other
hand, IOP had no influence on the production of thyroid hormones, but exerted an inhibitory effect
on all the forms of deiodinases, including DIO2 and DIO3 [219]. Similar investigations showed that,
in hypothyroid animals, in which RMR was significantly reduced compared to euthyroid animals,
both T3 and 3,5-T2 were able to significantly increase RMR. The administration of a single dose of T3 in
rats, resulted, indeed, in approximately a 35% RMR increase, which occurred 25–30 h after T3 injection,
and rose to a peak after 50–75 h. The T3-induced effect lasted up to 5–6 days after administration.
On the other hand, the same dose of 3,5-T2 induced a 40% RMR increase after 6–12 h, which rose to
a peak at 24–30 h and lasted 48 h [193]. Notably, if injected into euthyroid rats, T3 had both early
and late effects, but when injected together with actinomycin D, a drug able to block transcription,
the late effects of T3 were no more evident, while the early effects were still present, thus confirming
the idea that some T3 effects might be due to its intracellular deiodination to 3,5-T2 [185,193]. As a
whole, these findings supported the hypothesis of a mechanism of action of 3,5-T2 that ruled out the
transcriptional processes and which was independent of the nucleus. In other words, 3,5-T2 might be
involved in short-term effects induced by THs in physiological situations in which an increase in energy
expenditure was required. An example is the exposure to cold, a situation in which additional energy
is required to counteract the increase in heat loss. THs play a key role in cold adaptation processes,
as indicated by the experiments showing that hypothyroid rats survive to cold temperature only for
3–4 days [220]. There is strong evidence that, although with different mechanisms, both 3,5-T2 and T3
may increase the resistance to cold [220]. In cold-exposed hypothyroid rats, 3,5-T2 and T3 increase
animal energy expenditure and stimulate the oxidative capacity expressed in terms of Cytochrome
C Oxidase (COX) activity of tissues with a high metabolic rate, such as heart, skeletal muscle, liver,
and brown adipose tissue (BAT) [220]. However, while the stimulating activity of T3 on the trophic
activity of tissues are probably due only to its nuclear effects, the specific targets of 3,5-T2 appear to be
mitochondria, thus resulting in an improvement of the oxidative capacity of tissues.
In some experiments, in order to assess the specific effects induced by 3,5-T2 and T3 and to rule out
those of their metabolites, hypothyroidism was induced in rats by the concomitant administration of
PTU and IOP. Then, the daily energy expenditure was determined by continuous monitoring of oxygen
consumption and CO2 production. In hypothyroid rats, in which daily energy expenditure was low,
the administration of 3,5-T2 and T3 restored the normal values observed in euthyroid rats. The evidence
that 3,5-T2 is a metabolically active hormone was provided, in the same study, by the finding that it also
had stimulating effects on β oxidation of fatty acids [192]. All the 3,5-T2 effects reported above were
observed in experiments carried out in rats with a deficit of thyroid function. In order to investigate the
effects of 3,5-T2 in normal conditions, single injections of T3 were given to euthyroid rats and the results
were compared with those obtained after T3 administration to animals rendered hypothyroid and
treated, at the same time, with the above-mentioned deiodinase inhibitors [185]. The results of these
studies showed that: (1) The effect of T3 on RMR of euthyroid rats occurred approximately 25 h before
those observed in rats treated with PTU + IOP; (2) the first phase of the change in RMR of euthyroid rats
treated with T3 appeared to be very similar to that observed following 3,5-T2 administration; (3) the
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administration of T3 and actinomycin D to rats made hypothyroid by PTU + IOP treatments caused
a marked reduction of the early effects of the hormone, thus highlighting the need of deiodination
to produce the early effects of T3; and (4) the highest increase in the rate of RMR concurred with the
highest hepatic concentration of 3,5-T2. Overall, these results confirmed that the early increase in the
rate of RMR, occurring after the administration of T3 in euthyroid rats, was likely to be due to its
conversion to 3,5-T2 by deiodinases, an effect which is independent of actinomycin D [185].
All these findings indicated that the precursor of 3,5-T2 in vivo is T3. However, many attempts to
demonstrate a direct deiodination of T3 to give 3,5-T2 failed [204]. These findings, as well as the high
degree of 3,5-T2 variability in serum, hamper the complete understanding of the mechanisms that
generate 3,5-T2. Thus a few other hypotheses have been proposed: (1) In spite of all the above reported
evidences, T3 might not be the precursor to 3,5-T2; (2) for still-unknown reasons, T4/T3 concentration
in the blood might be not directly related to serum and/or tissue levels of 3,5-T2; (3) transformation
of T3 to 3,5-T2 might happen with different kinetics in different cell types and might depend on
tissue-specific factors; and, finally, (4) 3,5-T2 might be rapidly metabolized to other bioactive molecules.
4.2. Cellular Targets of 3,5-T2
Several observations support the hypothesis that mitochondria are the specific target of 3,5-T2.
For example, after an in vitro pre-incubation of liver homogenate with radioactive 3,5-T2, specific
binding sites, with high affinity (10-8 moles/liter) and low binding capacity (0.4–0.6 pmoles/mg protein)
were detected in rat liver mitochondria [221]. Competition experiments provided evidence that
unlabeled 3,3′-T2, T3, and T4 could all compete with 3,5-T2 for the same sites, but only when added at
high concentrations [221]. Notably, after isolation of mitochondria, a significant increase in the activity
of Cytochrome C Oxidase (COX) could be evidenced [222,223]. The effect was proposed to be mediated
by a direct binding of 3,5-T2 to COX that induced a conformational change of the oxidized enzyme,
evidenced by spectral changes [223]. This hypothesis was in agreement with previous analyses that
had identified two sites of the mitochondrial respiratory chain as targets of 3,5-T2, namely complex IV
(i.e., COX), which transfers electrons from the reduced cytochrome c to O2 to produce H2O, and the
reductases involved in the reduction of cytochrome C [224]. More specifically, the Va subunit of the
COX complex was identified as a critical binding site for 3,5-T2 [225]. The same study also showed that
the effects of 3,5-T2 on the COX complex consisted of a suppression of the allosteric inhibition of COX
by ATP, as the Va subunit is adjacent to the IV subunit, which binds ATP [225]. These findings also
stimulated a search for cytosolic 3,5-T2 binding sites, possibly involved in transferring the hormone to
the mitochondria. By photo-affinity labeling of rat liver cells, three proteins able to bind 3,5-T2 were
identified, with apparent molecular masses of 86, 66, and 38 kD, respectively [226]. In particular, the 38
kD protein was able to bind either 3,5-T2 or T3, but its affinity for 3,5-T2 was more elevated, and 3,5-T2
binding was independent of NADPH concentration. Conversely, binding of the 38 kD protein to T3
was NADPH-dependent. Thus, this cytoplasmic factor, by acting in a cellular redox state-dependent
manner (i.e., depending on the NADPH/NADP ratio), seemed to function as a reservoir of 3,5-T2 and
T3, and as a carrier as well [226]. A further effect of 3,5-T2 on mitochondria was suggested to depend
on increased absorption of mitochondrial Ca+2 [227]. Importantly, it has been known for a long time
that Ca+2 ions might trigger an enhancement of mitochondrial activity, due to the increased activity of
at least three mitochondrial dehydrogenases (i.e., pyruvate dehydrogenase, isocitrate dehydrogenase,
and α-ketoglutarate dehydrogenase), which could increase the amount of reduced substrates available
for the respiratory chain [228].
The effects of 3,5-T2 are not limited to mitochondria. In myocytes of newborn rats, T4, T3,
and 3,5-T2 were indeed found to significantly increase Na+ currents, as compared to untreated controls.
In contrast, as also observed for reverse T3 (rT3), MITs or tyrosine, the acidic metabolites of T3
and T4 (tetraiodothyroacetic acid, TETRAC, and triiodothyroacetic acid, TRIAC, respectively) had
no effect on Na+ currents. These acute effects of THs and their analogues on Na+ currents were
attributed to non-genomic mechanisms of action. T3 and 3,5-T2 also affected membrane transport
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systems, such as the Na+/H+ exchanger and the amino acid transport system of chicken embryo
hepatocytes [229]. Evidence was also provided on rapid non-genomic effects of THs during fetal
development and cellular differentiation: 3,5-T2 was able, in these studies, to mimic some of the
effects of T3, but less efficiently [230]. Thus, it is possible that 3,5-T2 is also involved in some of the
non-genomic T4/T3 effects described in Section 3.3. On the other hand, long-term effects of 3,5-T2 on de
novo lipogenesis (see Section 4.3) have been also reported [231]. Interestingly, 3,5-T2, at a concentration
of 0.1–1.0 µm, can also modulate energy metabolism in cardiomyoblasts, in both ex vivo and in vitro
models; in particular, this effect was found to be based on an increase of glucose consumption [232],
as also shown in skeletal muscle [233].
4.3. The 3,5-T2 and Lipid Metabolism
NAFLD is a pathological condition, widespread in wealthy societies, and characterized by altered
lipid metabolism, with consequent accumulation of fat in hepatocytes, increased oxidative stress,
and abnormal production of cytokines [234–236]. NAFLD is associated with visceral obesity and
cardiovascular risk factors [24]. This condition can also evolve into steatohepatitis, advanced fibrosis,
cirrhosis, and finally hepatocellular carcinoma [237]. The ectopic development of fat storage in the
liver was associated with alterations in the mitochondrial compartment. Both rats with steatotic liver
and patients with steatohepatitis showed a reduced OXPHOS capacity, peripheral insulin resistance,
and increased oxidative stress in hepatic mitochondria, although the ability to use fat as a metabolic
fuel was increased [29,238,239]. The increase in fatty acid oxidation stimulates, in turn, ketogenesis as
a compensatory mechanism. Increased mitochondrial β-oxidation has been also observed in the liver
of genetically obese (ob/ob) mice, with massive steatosis [240]. However, the increase in lipid oxidation
is not sufficient to handle the increased burden of hepatic free fatty acids (FFAs), so the remaining FFAs
are converted into triglycerides, which are partly deposited in the cytoplasm, thus causing steatosis.
Although the modulation of the caloric intake and increase of physical activity are the cornerstones
of the treatment of metabolic disorders [241–243], some experimental and clinical investigations were
aimed at finding out novel drugs that could be useful for the prevention and/or treatment of steatosis.
Thus, a variety of TRβ-specific agonists have been prepared and shown to cause significant decrease
of cholesterolemia and body weight [244–248]. For example, TRC150094, a functional analogue of
iodothyronine has been shown to reduce adiposity in HFD rats [249].
Besides using TH analogues and TR agonist, the effects of 3,5-T2 were evaluated in rats fed a
HFD over a long period. The results obtained in these studies indicated that in HFD rats, 3,5-T2:
(1) Reduced body weight and metabolic efficiency, without suppressing TSH levels; (2) decreased
the serum levels of cholesterol and triacylglycerols (TAG); (3) increased the hepatic mitochondrial
consumption of O2 and oxidation of fatty acids; (4) activated the proton mitochondrial dispersion in
hepatocytes; and (5) reduced the mitochondrial oxidative stress [250]. An interesting aspect concerns
the changes in efficiency of substrate utilization in steatotic animals. The decrease in proton loss and
the increase in the body weight/caloric intake ratio clearly indicate a more efficient use of energy
in these animals in comparison with healthy controls. On the other hand, after 3,5-T2 treatment,
the efficiency of the energy use clearly decreased. While T3 action on mitochondria is mainly mediated
by nuclear induction of the synthesis of uncoupling proteins (UCPs), fundamental for OXPHOS
uncoupling, and thermogenesis [251–256], as discussed in the previous paragraph, 3,5-T2 effect is
probably mediated by a direct interaction with the COX respiratory complex [223,225]. Interestingly,
in hypothyroid rats treated with 3,5-T2, besides the already mentioned increase of oxygen consumption,
a rise in the ATP synthase activity could be observed; this effect could be explained, at least in part,
by increased levels of cardiolipin [257]. Notably, however, an increase of both mRNA and proteins
levels of the enzyme subunits was also observed, thus suggesting a T2-induced nuclear effect [258].
In general, 3,5-T2, contrary to T3, does not induce proton leak (i.e., it does not induce synthesis of
UCPs), but is somehow able to influence the kinetic properties of the respiratory pathways [259].
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Notably, administration of 3,5-T2 for four weeks induced a further increase in β-oxidation and
the carnitine palmitoyltransferase (CPT) system activity. These changes, responsible for a better
compensation of the hepatic load of FFAs, could be one of the mechanisms that make 3,5-T2 able
to improve steatosis. Notably, the increase in the rate of mitochondrial respiratory processes could
enhance the re-oxidation of the reduced coenzyme NADH to NAD+, necessary for both β-oxidation
and the tricarboxylic acid cycle. All together these actions would lead to a higher fat consumption [250].
Actually, administration of 3,5-T2 decreases hepatic mitochondrial oxidative stress, as indicated by the
significant decrease of H2O2 [250] (paragraph 4.4).
The role of 3,5-T2 in HFD rats was also evaluated, in comparison with euthyroid rats receiving
a standard diet (N) [198]. The results of these experiments showed that in HFD-T2, 3,5-T2 was able
to reduce both adiposity and serum levels of free fatty acids, triglycerides, and cholesterol, without
inducing any clinical sign of thyrotoxicosis. In HFD animals, β-oxidation levels were 30% higher,
the activity of acetyl-coenzymeA-carboxylase (ACC) significantly lower (−65%), and the activity of
carnitine palmitoyl-transferase system (CPT) 38% higher than in N animals. Notably, the levels of
AMP-activated protein kinase (AMPK), which inhibits ACC activity in different physiological conditions,
were also decreased. The reduced ACC activity observed in HFD rats was probably due to a reduced
amount of the enzyme, rather than to its decreased activity. Thus, the increase in fatty acid oxidation
in HFD rats may be due to a reduced level of malonyl-CoA (the product of the reaction catalyzed by
ACC) that, in turn, allows activation of the CPT system (normally inhibited by malonyl-CoA) [198].
Treatment with 3,5-T2 further increased fatty acid oxidation by significantly activating AMPK and
CPT activity, without increasing CPT1 mRNA levels and without further inhibiting ACC activity [198].
These results suggest that 3,5-T2 increases fatty acids entering into the mitochondria by regulating
CPT1 activity in an AMPK-dependent manner and ACC-malonyl-CoA-independent manner [198].
The possible existence of a malonyl-CoA-independent control mechanism on the hepatic activity of
CPT1 is supported by some studies that showed that stimulation of hepatic fatty acid oxidation can
also use a malonyl-CoA-independent pathway that involves an AMPK-mediated phosphorylation of
cytoskeletal components, leading to CPT1 stimulation [260,261]. Notably, the increase in body weight
and adiposity observed in HFD rats clearly indicates that: (1) An increase in hepatic fatty acid oxidation
is not sufficient, per se, to prevent fat accumulation, due to HFD continuous consumption, and (2) the
TH-dependent reduction of adiposity is due to a less efficient use of the substrates. One well-known
TH effect is the ability to cause OXPHOS uncoupling by allowing the energy of the proton gradient
to be dissipated as heat [262]. In HFD-T2 rats, 3,5-T2 caused a less efficient use of lipid substrates by
reducing the synthesis of ATP and inducing a greater fat combustion, which was indeed more elevated
in HFD-T2 than in HFD rats [198]. The physiological consequences of these effects were an increase in
energy expenditure and a slight increase of body temperature. This suggested that proton gradient
dissipation had a decisive role in the effects exerted by 3,5-T2 on substrate utilization efficiency and,
consequently, on adiposity [198].
To assess the hypothesis that 3,5-T2 acts on rat hepatocytes through nuclear receptor-independent
mechanisms, its effects were also studied in a well differentiated rat hepatoma cell line (FaO) [263],
which lacks functional TRs, as also demonstrated by the absence of constitutive mRNA expression for
both TRα1 and TRβ1. An in vitro model of “steatosis” was developed [264,265] by exposing FaO cells
for 3 h to a mixture of oleate/palmitate (2:1, 0.75 mm final concentration), which closely mimics plasma
FFA levels of patients with metabolic syndrome [266].
Normally, FFAs that enter the liver undergo esterification to produce TAGs, which are then
stored, for later use as metabolic fuel, in the form of cytosolic lipid droplets (LDs). Typically, LDs are
composed of a core of neutral lipids surrounded by phospholipids and proteins of the PAT family,
among which the adipose differentiation-related protein (ADRP), and the tail-interacting protein of
47 kDa (TIP47) [267–269]. Among these proteins, ADRP is involved in adipocyte differentiation and
promotes lipid incorporation in LDs, while inhibiting FAA oxidation. Its expression increases in liver
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steatosis, and in model animals exposed to HFD [269,270], and is under the control of peroxisome
proliferator-activated receptors (PPARs) [270,271].
PPARs play a key role in lipid metabolism [272,273]. PPARα improves catabolism and
lipid mobilization [274], while PPARγ promotes lipid synthesis and LD formation [275–277] and
PPARδ increases the synthesis of high-density lipoprotein (HDL), inhibits LD formation in the liver,
improves FFA catabolism, and promotes energy uncoupling in adipose and muscular tissues [278,279].
Furthermore, PPAR β/δ play a crucial role in hepatic lipid homeostasis and insulin sensitivity,
by activating glycolysis and lipogenesis [280]. The relative concentrations of the different PPARs
change depending on both physiologic and pathological conditions [281]; moreover, specific lipid
mixtures used to feed both the animals and the isolated cells can have a significant impact on the
dynamic equilibrium of PPAR regulation [264,282]. All the PPAR subtypes (PPARα, PPARγ, and PPARδ)
are constitutively expressed in FaO rat hepatoma cells [275,276]. Notably, treatment of steatotic FaO
cells with 3,5-T2 or T3 for 24 h reduced TAG content as well as the number and size of LDs. The effects
of 3,5-T2 were also accompanied by a reduction of PPARγ [282,283]. These findings demonstrated
that the direct hypolipidizing effect exerted both by 3,5-T2 and T3 on the hepatic cells can occur even
in the absence of TRs [264,265,282] and are based on the ability to activate pathways affecting TAG
deposits within LDs and to promote mitochondrial oxidation and/or exocytosis of the very low density
lipoproteins (VLDL) [284]. The 3,5-T2-mediated effects in steatotic hepatocytes in culture also include
the recruitment to LDs of the adipose triglyceride lipase (ATGL), which might be an early mediator of
iodothyronine action [282,285]. However, it has been also reported that neither T2 nor T3 increased
AMPK-mediated phosphorylation of ATGL, while, on the basis of a metabolomics analysis, lipophagy
(i.e., autophagy of lipids) seemed to be the major mechanism at work for triglyceride digestion, at least
in the first phase of hepatic adaptation to HFD [286].
Recently, in primary human hepatocytes, freshly prepared from donors and grown on Matrigel,
not only 3,5-T2 but also 3,3′-T2 were able to reduce lipid accumulation, by decreasing expression of
lipogenic enzymes. Moreover, it was found that they do so by inhibiting the mammalian target of
rapamycin complex 1 (mTORC1), through an AMPK-mediated effect, and activating mTORC2 [211].
T3 normally also stimulates hepatic fatty acid and cholesterol syntheses. Both syntheses are
also fundamental for the turnover of cell membrane components. These T3 effects are mediated
by its binding to TRs, and by the consequent transcriptional activation of genes encoding lipogenic
enzymes; genes encoding enzymes like ACC and fatty acid synthase (FAS) contain, indeed, TREs in
their promoters [287]. Moreover, TREs are also contained in the promoter of the gene encoding the
transcription factor known as carbohydrate response element-binding protein (ChREBP), which can
exert a further stimulatory effect on transcription of the lipogenic genes [287]. In HFD rats treated
with T2 (25 µg/100 g of body weight), expression of all these genes, and activity of the sterol
regulatory element-binding proteins 1c (SREBP-1c), also involved in activation of lipogenic genes,
is downregulated [288]. On the other hand, in the same rats, T3 (2.5 µg/100 g of body weight) did not
repress ChREBP, even if it repressed expression of SREBP-1c (this latter gene contains a negative TRE
in its promoter) [288]. Interestingly, in the HEPG2 cancer cells, it was found that 3,5-T2 can block the
proteolytic cleavage (and, thus, activation) of SREBP, without any effect on its expression [289]. In the
same experiments, it was also found that apoptosis of HEPG2 cells seemed to occur, after 12 h of T2
treatment [289].
The effect of 3,5-T2 seems to be the opposite in the liver of hypothyroid rats, in which the
hormone, after a long-term treatment (15 µg/100 g of body weight, for 1 week) was found to activate
genes involved in de novo lipogenesis, by increasing the amount of the nuclear forms of SREBP
and ChREBP [231]. Although further studies are necessary to better understand the mechanisms
underlying these effects, it may be hypothesized that the 3,5-T2 nuclear effects observed in hypothyroid
rats are due to SREBP and ChREBP, while 3,5-T2 should have an indirect effect, due to its ability to
activate a still-unknown pathway leading to SREBP/ChREBP activation.
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4.4. Effects of T2 on Lipid Peroxidation
A high-fat diet presumably provides more long-chain FFA capable of entering hepatocytes,
thus inducing upregulation of PPARα, which, in turn, controls the expression of genes
involved in mitochondrial and peroxisomal fatty acid β-oxidation, as well as in microsomal
omega-oxidation [290,291]. The expression of PPARα, and of genes regulated by it, increases indeed in
the liver of obese rodents fed fat-rich diets [292–294]. These effects have been also highlighted in liver
biopsies from patients with NAFLD [295].
Fatty liver mitochondria oxidize FFA at a higher rate and produce higher amounts of superoxide
when compared to mitochondria from normal liver [296,297]. In addition, increased oxidation of long
chain FFA in peroxisomes produces higher amounts of hydrogen peroxide (H2O2), in the reaction
catalyzed by acyl-CoA oxidase (AOX) [298]. The excess of reactive oxygen species (ROS) in turn
induces a higher level of liver lipid peroxidation [234].
Hepatocytes try to counteract the cellular oxidative stress by increasing the expression of
antioxidant enzymes. Fatty liver mitochondria show a 70% greater manganese superoxide dismutase
activity [296], and peroxisomal enzymes (i.e., catalase) involved in H2O2 metabolism are also stimulated
in HFD [298]. The cell protective mechanisms activated in HFD also include the synthesis of antioxidant
molecules such as glutathione [299], and metallothioneins (MTs). MTs are low-molecular weight
(6–7 kDa), highly conserved, and ubiquitous cysteine-rich proteins, with high affinity for divalent
metals; they are involved in some essential biological functions, including homeostatic regulation of
zinc and copper availability, detoxification from heavy metals, and scavenging of free radicals [300–304].
A number of stimuli induce their expression, including acute phase response, cold and heat stress,
and some hormones, such as the growth hormone (GH) [305].
Notably, transgenic mice over-expressing MT are more protected from hepatic oxidative stress
associated with alcoholic liver disease [306]. On the other hand, the observation that MT I/II knockout
mice become mildly obese, suggests a role for MTs as modulators of energy metabolism [307]. MTs also
play a key role in liver damage and liver regeneration [308,309]. Evaluation of the transcription profiles
of the two isoforms constitutively expressed in the liver, namely, MT-1 and MT-2 [300], highlighted
upregulation of both isoforms in rats fed HFD, thus suggesting their potentially protective role in the
liver. In addition, in obese subjects, MT-2 mRNA levels are also increased in the adipose tissue [310].
ROS can induce the expression of MTs through the interaction with the antioxidant response elements
(ARE), and with the metal response elements (MRE), present in the MT gene promoters and recognized
by different factors, including the metal-responsive transcription factor 1 (MTF-1) [311–313]. Finally,
it is worth noting that MTs are located in the intermembrane space of the mitochondria of the liver
cells and, when imported into liver mitochondria, they can inhibit respiration [314].
All the above-described effects of HFD were partially neutralized by the administration of
3,5-T2 to rats. Treatment with 3,5-T2 reduces the activities of both superoxide dismutase (SOD) and
catalase (CAT), thus suggesting that iodothyronines have a protective effect against excessive FFA
oxidation [283,298]. After 30 days of 3,5-T2 treatment, upregulation of PPARα was also counteracted.
Moreover, 3,5-T2 prevented both lipid peroxidation (measured as thiobarbituric-reactive substances
(TBARS)) and the increase of MT-2 in the liver [298]. Interestingly, 3,5-T2 did not alter the transcription
profile of MTs in the liver of rats fed a standard diet, thus suggesting that the effects of 3,5-T2 on hepatic
expression of MTs are secondary to the effects of the hormone on molecules and/or pathways associated
with fat intake. In particular, the effects of 3,5-T2 might be explained by a selective stimulation of the
metabolism of fatty acids in the mitochondria, at the expense of peroxisomal and microsomal oxidation.
It is also possible that the effects of 3,5-T2 on the liver depend on a reduced influx of fat in hepatocytes,
caused by a primary effect of 3,5-T2 on other tissues, such as the adipose tissue.
Importantly, an increase of oxygen consumption and of oxygen radical formation also cause
damage to the mitochondrial DNA (mtDNA), that is, per se, more vulnerable than the nuclear.
The 3,5-T2, by reducing mitochondrial oxidative stress, has been found to be able to also reduce mtDNA
damage [315].
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4.5. Effects of 3,5-T2 on Adipose Tissue
Two main kinds of adipose tissues, with different ontogenic origin and lineage, exist in the body:
The white adipose tissue (WAT) and the brown adipose tissue (BAT) [32]. WAT stores triglycerides,
but also produces adipokines [316]. On the other hand, BAT dissipates energy in the form of heat [32].
Endotherm animals have the ability to maintain a quite constant body temperature almost
independently of environmental conditions. This ability is fundamental as it is directly related to the
animal performance in the everyday life [317]. When heat loss is higher than heat production through
basal metabolism, there are two possibilities for producing extra heat: Shivering and non-shivering
thermogenesis [318]. Shivering response is given by muscle contraction, while non-shivering
thermogenesis depends on nervous signals transmitted from the brain via the sympathetic nervous
system (SNS) to BAT. Transmission of these signals allows release of noradrenalin at the level of BAT and
activation of triglyceride hydrolysis, followed by free fatty acid β-oxidation in the mitochondria [318].
An important role in this process is played by the uncoupling protein 1 (UCP1); as discussed in Section 4.3,
UCP1 allows proton leak across the mitochondrial internal membrane, thus uncoupling OXPHOS
and allowing dissipation as heat of part of the energy stored in the proton gradient [319]. OXPHOS,
per se, already releases a considerable amount of heat since not all the enthalpy deriving from substrate
oxidation is converted into ATP synthesis and this basal heat production is particularly effective in
tissues, such as BAT, that show an intense oxidative metabolism. As already discussed, a highly active
OXPHOS also leads to ROS formation. Notably, genetic and pharmacological experimental procedures
that increase adipocyte ROS levels, or the related oxidation of cellular thiols, have been shown to
stimulate adipocyte thermogenesis; in other words, a shift in the oxidative/reducing equilibrium
is determined in BAT by induction of acute thermogenic respiration. It is worth noting that these
modifications are reversible and do not cause a generalized oxidative stress [319]. Moreover, it seems
that UCP1 is not the only actor in the mitochondrial proton leak and thermogenesis.
THs are essential for the thermogenic function of BAT, in synergy with the SNS [209,320].
BAT contains both TRα and TRβ, which seem to mediate the T3-dependent effects in synergy with the
SNS and transcription of the UCP1 gene, respectively [209]. TRβ also stimulates UCP1 transcription in
the WAT. In addition, in BAT, TH-dependent thermogenesis is stimulated by noradrenalin. This latter
effect is due to stimulation of DIO2 through DIO2 gene transcription, on one hand, and stabilization of
the protein, through its de-ubiquitination, on the other hand [209,321].
Like T3, 3,5-T2 also has an effect on BAT thermogenesis: (1) It improves survival in the cold of
hypothyroid rats; (2) by directly binding, as already mentioned, to COX, it increases the oxidative
potential of the cell; and (3) it induces an increase in mitochondrial biogenesis. Somehow, 3,5-T2 also
has an effect on the number of noradrenergic fibers, and adrenergic stimulation is probably responsible
for the 3,5-T2-dependent higher vascularization of BAT [209,322].
Most interesting, it has been shown that 3,5-T2 can induce “browning” in the WAT of T2-treated rats.
With the term “browning” is described the fact that, when stimulated by physiological factors, such as
THs, exercise, or diet, able to increase thermogenesis, WAT can acquire a BAT-like phenotype [323,324].
The process mainly occurs in the subcutaneous WAT and has been reported to involve some microRNAs
(e.g., miR-133a and MiR196a) [324]. Recently, the effect of 3,5-T2 has been also studied, by proteomic
analysis, in the visceral adipose tissue of HFD-rats, where a clear pro-angiogenic action was observed,
together with reduction of proteins involved in lipid storage or in oxidative stress [325].
Although the mechanisms underlying browning have not been yet clarified, the process is of the
utmost importance because an increase of BAT-like tissue also increases thermogenesis and, hence,
stimulates the metabolism of the entire organism. Thus, to find factors able to induce browning could
be an important way to improve metabolic disorders, such as metabolic syndrome and diabetes. In this
context, 3,5-T2 seems to be a promising molecule.
Int. J. Mol. Sci. 2020, 21, 4140 22 of 40
4.6. The Ins and Outs of 3,5-T2 Research
In summary, a variety of experiments on model animals have clearly shown that 3,5-T2 behaves
as a hormone. The peculiar property of 3,5-T2 is its mainly nucleus-independent activity. Although it
can bind TRs, even if with a much lower affinity than T3, 3,5-T2′s main mechanism of action seems
indeed to be based on a direct interaction with mitochondria, at the level of which 3,5-T2 is able to
potentiate mitochondrial activity and thermogenesis.
As discussed above, the treatment with 3,5-T2 may prevent the damage caused by HFD and
reduce the circulating levels of LDL and TAG, as well as hepatic steatosis in overweight patients.
It has been reported that the hormone may also reduce a pre-existing accumulation of fat in the rat
liver [191]. In humans, a few studies have confirmed that the administration of 3,5-T2 can increase the
resting metabolic rate, also reducing adiposity and body weight without side effects [250]. Interestingly,
through molecular fingerprinting experiments, a strong positive association has been found between the
3,5-T2 levels in the human serum and compounds related to coffee consumption [326]. Taken together,
all these finding are encouraging and provide evidence that 3,5-T2 might become a therapeutic agent
of utmost importance.
On the other hand, we still lack clear demonstration that the effects observed in mice/rats can be
completely reproduced in our species. Experiments in humans are indeed still limited, and, as discussed,
it is not yet clear whether 3,5-T2 is produced in peripheral tissues at significant concentrations It
is not completely understood, for example, whether blood concentrations of 3,5-T2 are related or
not to intracellular concentrations of the hormone: It is possible that T3 deiodination to 3,5-T2 is
controlled by tissue factors, differently regulated, for example, in a tissue-specific and/or in a metabolic
state-specific manner. From this point of view, it is intriguing that no significant difference was found
in serum 3,5-T2 of hypothyroid and hyperthyroid patients [202] and that no significant correlation
was evidenced between serum 3,5-T2 and the main THs [203]. As mentioned, a further problem arises
because of contamination by T3 of the commercial preparations of 3,5-T2, used as standards in the
measurements [20,204].
Even with these limitations, 3,5-T2 is widely considered a bioactive molecule [20,59,113,191,204–211].
Thus, in summary, the field is very promising and might offer important advancements in the therapy of
obesity and related pathologies. However, it is mandatory to conclusively understand how intracellular
3,5-T2 is produced and how this production is regulated. Moreover, as 3,5-T2 can be transformed into
other metabolites, the entire metabolic process in which this hormone is involved should be clarified.
5. Conclusions and Perspectives
As discussed above, in the last two decades, a multitude of studies have highlighted that the
effects of THs on cells do not rely only on their nuclear action, but also on a variety of other pathways,
sometimes involving their metabolites. Among these latter molecules, 3,5-T2 has attracted much
interest since it was found to be effective in increasing the resting energy. Most important, 3,5-T2 seems
to have a very rapid effect, probably due to its ability to interact directly with mitochondria. In addition,
at least at low concentration, it does not seem to cause thyrotoxic effects [20,188]. A general summary
of TH metabolism and effects in the target cell, including formation and mitochondrial targeting of
3,5-T2, is shown in Figure 7.
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Figure 7. General summary of T4 (yellow squares), and T3 (light blue triangles) production and
transport to the peripheral tissues. As indicated by the thickness of the light blue arrows, T4 is
released from the gland, and circulates in the blood at a much higher concentration than T3. In the
blood, two main TH transporters are present: the thyroxine-binding globulin (TBG), and transthyretin
(TTR). THs enter the cells through transmembrane transporter proteins, such as the monocarboxylate
transporters (MCTs), the organic anion transporters (OATPs), and the L-type amino acid transporters
(LATs). Once in the target cell, T4 is deiodinated by deiodinases 1 and 2 (DIO1/2) to T3. T3 is the most
active form since it binds with the highest affinity to the nuclear receptors. In addition, T3 probably
also binds some truncated forms of receptors targeted to mitochondria, where T3 might regulate also
transcription of genes present in the mitochondrial DNA (mtDNA). T3 can be also deiodinated to 3,5-T2
and this latter molecule can reach the mitochondria that seem to represent its main target. Notably,
THs (and especially T4, given its much higher concentration in the circulation) can also bind integrin
αvβ3 (Int αvβ3), thus activating an intracellular pathway that involves the Mitogen-activated protein
kinase (MAPK), and the PhosphatidylInositol-3-Kinase (PI3K). Moreover, truncated forms of TRs are
palmitoylated and inserted into the inner leaflet of the plasma membrane (membrane-bound TRs,
mbTR), from which they can bind THs and activate a pathway that involves the cGMP-dependent
protein kinase II (PKGII) (TR).
Notably, beside 3,5-T2, other TH endogenous metabolites have been reported to be active and to
have interesting effects on a variety of cellular activities. For example, 3,5,3′-triodothyroacetic acid
(TRIAC), derived from deamination of T3, can bind both TRβ and TRα with similar or even higher
affinity than T3 and has been proposed as an alternative TR ligand for therapeutic aims, also because
it does not use MCT8 as a membrane transporter, and can thus offer an opportunity to treat the
Allan–Herndon–Dudley syndrome, a developmental disorder that affects the central nervous system
and is due to an MCT8 mutation [20,113]. Similarly, 3,3’,5,5’-tetraiodothyroacetic acid (TETRAC),
derived from deamination of T4, is a powerful ligand of αvβ3 receptor, acting as an efficient competitor
for T4/T3 binding, thus inhibiting their effects in a variety of cellular models of tumorigenesis [20,327].
Even rT3 has been reported to induce non-genomic responses in Sertoli cells [328]. Finally, THs
can also undergo decarboxylation, giving rise to thyronamines, such as 3-iodothyronamine (T1AM).
Recently, it was reported that decarboxylation is catalyzed by ornithine decarboxylase (ODC) that
seems to use as substrates only T4 and 3,5-T2 [329]. In detail, the biosynthetic pathway should involve
Int. J. Mol. Sci. 2020, 21, 4140 24 of 40
TH deiodination to 3,5-T2, followed by its decarboxylation and further deiodination by DIO3 to
T1AM [210]. Thus, 3,5-T2 should be the T1AM’s immediate precursor. Although the membrane
transporters for T1AM have not been yet identified, it has been suggested that, given its ability to bind
low-density lipoproteins (LDL), its cellular uptake might be coupled to LDL endocytosis [210,330].
T1AM does not bind TRs, but is a high-affinity agonist of trace amine-associated receptor 1 (TAAR1),
a membrane G protein-coupled receptor, and probably also of other members of the family. As it
happens for other aromatic amines (cathecolamines, serotonine, etc.), T1AM seems to be a signal
molecule with a variety of effects, such as: (1) Reduced heart rate and contractility. (2) decreased
insulin secretion and increased glucagon secretion, (3) lipid catabolism, (4) pro-learning effects, and (5)
decreased proliferation of tumor cell lines [210,331].
Notably, the fact that T1AM derives from 3,5-T2 suggests that some of the effects of this latter
molecule might be mediated by T1AM.
In conclusion, it is now clear that the canonical mechanisms of action of THs are no more sufficient
to explain all the effects of these important hormones and that at least some of their metabolites are
also involved in their activities. If, on one hand, these discoveries opened an incredibly wide field of
analysis, at the same time, we are now realizing that these novel thyroid hormones can offer unforeseen
opportunities in the therapy of a variety of human metabolic disorders, provided that we can clearly
understand how they are produced, how they are catabolized, and how their action is modulated in
our body.
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